Latest Sedatives Stories
ANN ARBOR, Mich., Jan.
Need the help of a pill to catch some zzzâ€™s? According to a new study youâ€™re not alone; the use of prescription sleep aids nearly tripled among young adults between 1998 and 2006.
Results Show Successful Clinical Validation of Pharmacodynamic Effect REDWOOD CITY, Calif., Jan.
The largest proportions of all insomnia-related expenses are attributed to lost job productivity, absences from work and alcohol used as a sleep aid.
FDA to review Intermezzo(R) (zolpidem tartrate sublingual lozenge) as the first sleep aid specifically designed for the treatment of middle-of-the-night awakenings PT. RICHMOND, Calif., Dec.
WOODCLIFF LAKE, N.J., Dec. 14 /PRNewswire/ -- Eisai Corporation of North America today announced that the U.S.
US-based pharmaceutical company Sepracor has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion recommending to grant a marketing authorization for Lunivia brand eszopiclone in the EU for the treatment of insomnia.
Sepracor Inc. (Nasdaq: SEPR) today announced that the EMEA's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending to grant a marketing authorization for LUNIVIA(R) brand eszopiclone in the European Union (EU) for the treatment of insomnia.
PT. RICHMOND, Calif., Oct.
AstraZeneca has received the FDA's approval for once-daily Seroquel extended-release tablets for the acute treatment of the depressive episodes associated with bipolar disorder, the manic and mixed episodes associated with bipolar I disorder, and the maintenance treatment of bipolar I disorder as adjunctive therapy to lithium or divalproex.